ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1012

Inhibition of Inflammation and Oxidative Stress in Systemic Sclerosis (SSc) Macrophages

Rajan Bhandari1, Michael Ball2, Saemi Han2, Kathleen Aren3, Mary A. Carns3, Monique Hinchcliff4, Michael L. Whitfield5, Karen Liby6 and Patricia A. Pioli7, 1Geisel School of Medicine at Dartmouth, lebanon, NH, 2Geisel School of Medicine at Dartmouth, Lebanon, NH, 3Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, 4Rheumatology, Northwestern University, Chicago, IL, 5Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH, 6Michigan State University, East Lansing, MI, 7Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: drug treatment, Inflammation, Macrophage, scleroderma and stress

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Session Title: Innate Immunity Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease of unknown etiology that is characterized by vasculopathy, fibrosis, and inflammation. Our work and that of others have implicated MØs in SSc pathogenesis and thus targeting MØs may have significant therapeutic benefit. We have shown that MØs are aberrantly activated in SSc, releasing inflammatory mediators and inducing activation of fibroblasts. We now show that the synthetic oleanane triterpenoid CDDO-methyl ester (CDDO-Me) inhibits immune activation and oxidative stress in SSc MØs, resulting in inhibited expression of TGF-b, CCL2, and IL-6 and enhanced activation of Nrf2 signaling.

Methods: Plasma and PBMCs were obtained from whole blood of 7 SSc patients or 5 healthy age and gender-matched control subjects following informed written consent. CD14+monocytes were isolated from PBMCs using magnetic bead selection, and were cultured with either autologous or allogeneic plasma for 7 days to differentiate the cells into MØs. Immune activation studies were performed using 10 ng/ml LPS. RNA expression in MØs was analyzed using qRT-PCR, and protein expression and secretion were monitored using flow cytometry and by ELISA.

Results: CDDO-Me markedly inhibits basal mRNA and protein expression of TGF-b, CCL2, and IL-6 in SSc MØs, and attenuates surface expression of CD163 and CD206, which are upregulated on pro-fibrotic SSc MØs. We further demonstrate that CDDO-Me upregulates targets of Nrf2 activation in SSc MØs, suggesting CDDO-Me attenuates oxidative stress in these cells. CDDO-Me treatment does not impair SSc MØviability.

Conclusion: Our data suggest that CDDO-Me attenuates inflammatory activation and induces anti-oxidant activity in SSc MØs. For the first time, we have shown that CDDO-Me treatment attenuates the pro-fibrotic activation profile of SSc MØs. For the first time, we have also shown that CDDO-Me inhibits expression of surface markers and cytokines associated with SSc inflammation and pathogenesis. In addition to regulating these factors, CDDO-Me also induces Nrf2 activation in SSc MØs. As CDDO-Me is currently undergoing Phase III clinical trial testing in patients with pulmonary arterial hypertension, a frequent complication and leading cause of death in SSc, potential repositioning of this drug to treat SSc is especially exciting. Because there are still no FDA-approved disease-modifying therapies that target innate immune activation in SSc, CDDO-Me may be a potentially important drug in our arsenal of therapeutics to combat MØ activation in this disease.


Disclosure: R. Bhandari, None; M. Ball, None; S. Han, None; K. Aren, None; M. A. Carns, None; M. Hinchcliff, None; M. L. Whitfield, None; K. Liby, None; P. A. Pioli, None.

To cite this abstract in AMA style:

Bhandari R, Ball M, Han S, Aren K, Carns MA, Hinchcliff M, Whitfield ML, Liby K, Pioli PA. Inhibition of Inflammation and Oxidative Stress in Systemic Sclerosis (SSc) Macrophages [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/inhibition-of-inflammation-and-oxidative-stress-in-systemic-sclerosis-ssc-macrophages/. Accessed May 25, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inhibition-of-inflammation-and-oxidative-stress-in-systemic-sclerosis-ssc-macrophages/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.